The University of Texas MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2025

100 $

+ Include: 74 videos + 61 pdfs, size: 33.1 GB

+ Target Audience: hematology/oncology physicians, fellows and practicing internists

Description

+ Include: 74 videos + 61 pdfs, size: 33.1 GB

+ Target Audience: hematology/oncology physicians, fellows and practicing internists

+ Sample video: contact me for sample video

+ Information:

Date & Location: Monday, September 15, 2025, 7:00 AM – Saturday, September 20, 2025, 5:30 PM, MD Anderson – Virtual

Target Audience:
Specialties – Colon and Rectal Surgery, Gynecologic Oncology, Hematology, Medical Oncology, Neurological Surgery, Obstetrics and Gynecology, Thoracic Surgery, Urology
Professions – Nurse – APRN, Nurse – LVN, Nurse – RN, Pharmacist, Pharmacy Technician, Physician (MD or DO), Student or Trainee
Overview

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

Objectives
At the conclusion of this activity, learners will be able to:
  1. Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.
  2. Utilize current standards of care for patients with cancer, blood disorders and malignancies.
  3. Demonstrate proficiency of knowledge in hematology and medical oncology.
  4. Incorporate recent advances in management of hematologic and oncologic patients.

 

+ Topics:

Schedule

Reviews

There are no reviews yet.

Be the first to review “The University of Texas MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2025”

Your email address will not be published. Required fields are marked *